Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 12/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | HINT1 | P49773 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19493308 | 1.00 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL18927167 | 1.00 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL17304163 | 1.00 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL18954874 | 1.00 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL21073923 | 1.00 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL668541 | 0.98 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL19493331 | 0.97 | TYMP (0.41) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL19485496 | 0.95 | KDM4E (0.38) | TYMPKDM4ETAS1R3TAS1R1NT5E | |
| SCHEMBL17301037 | 0.95 | KDM4E (0.38) | TYMPKDM4ETAS1R3TAS1R1NT5E | |
| SCHEMBL23138150 | 0.93 | TYMP (0.45) | TYMPKDM4ETAS1R3TAS1R1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308216-A1 | PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-01 | — | — | US | disclosed |
| US-10696710-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200140477-A1 | PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-05-07 | — | — | US | disclosed |
| US-10633411-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-04-28 | — | — | US | disclosed |
| US-10508129-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308216-A1 | PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY | CGAS, GMPS, STING1 | TYMP 221/4885KDM4E 4753/4885TAS1R3 2859/4885 |
| US-10508129-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | CGAS, GMPS, STING1 | TYMP 221/4885KDM4E 4753/4885TAS1R3 2859/4885 |
| US-20200140477-A1 | PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY | CGAS, GMPS, STING1 | TYMP 221/4885KDM4E 4753/4885TAS1R3 2859/4885 |
| US-10696710-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | CGAS, GMPS, STING1 | TYMP 221/4885KDM4E 4753/4885TAS1R3 2859/4885 |
| US-10633411-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | CGAS, GMPS, STING1 | TYMP 221/4885KDM4E 4753/4885TAS1R3 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.